Symbols / TNYA Stock $0.97 -3.01% Tenaya Therapeutics, Inc.
TNYA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Ratings
Current target
$0.97
Low
$2.00
High
$8.00
Mean
$4.20
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-12 | main | Chardan Capital | Buy → Buy | $8 |
| 2025-12-18 | main | Canaccord Genuity | Buy → Buy | $5 |
| 2025-12-12 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-12-12 | main | Chardan Capital | Buy → Buy | $8 |
| 2025-11-10 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-07 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-05-09 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-04-25 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-13 | main | Canaccord Genuity | Buy → Buy | $6 |
| 2025-03-12 | main | Morgan Stanley | Overweight → Overweight | $5 |
| 2025-03-12 | main | Chardan Capital | Buy → Buy | $9 |
| 2025-03-11 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-12-18 | main | Chardan Capital | Buy → Buy | $18 |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-11-26 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
- Why Tenaya Therapeutics (TNYA) Is Up 26.6% After New TN-401 Data Near-Term Catalysts - simplywall.st Mon, 11 May 2026 11
- $TNYA stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Mon, 04 May 2026 14
- TNYA pulls back after hours following significant $1.13B deal-spurred rally - MSN Sat, 25 Apr 2026 01
- Tenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed? - Yahoo Finance Mon, 11 May 2026 19
- Tenaya Therapeutics (TNYA) seeks approval for larger equity plan and director slate - Stock Titan hu, 16 Apr 2026 07
- Should I buy Tenaya Therapeutics (TNYA) - Zacks Investment Research Wed, 06 May 2026 07
- Two heart gene therapy readouts near as Tenaya adds Alnylam deal - Stock Titan Wed, 06 May 2026 20
- What date does Tenaya Therapeutics's (TNYA) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research Wed, 06 May 2026 07
- Tenaya Therapeutics, Inc. (TNYA) reports Q1 loss, misses revenue estimates - MSN Mon, 11 May 2026 09
- Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed - Yahoo Finance Sun, 14 Dec 2025 08
- Tenaya Therapeutics (TNYA) Valuation Check As TN-401 Gene Therapy Data Approaches ASGCT 2026 - simplywall.st Sun, 10 May 2026 06
- $TNYA stock is up 20% today. Here's what we see in our data. - Quiver Quantitative hu, 29 Jan 2026 08
- Tenaya Therapeutics (NASDAQ: TNYA) trims Q1 loss, lands Alnylam deal - Stock Titan Wed, 06 May 2026 20
- Tenaya to show 1-year heart gene therapy data in late-breaking talk - Stock Titan Mon, 27 Apr 2026 07
- Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance hu, 12 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
93.33
-19.51%
|
115.95
-11.62%
|
131.19
+4.44%
|
125.62
|
| Research And Development |
|
68.61
-20.91%
|
86.74
-11.52%
|
98.04
+3.70%
|
94.54
|
| Selling General And Administration |
|
24.72
-15.35%
|
29.21
-11.91%
|
33.16
+6.66%
|
31.08
|
| General And Administrative Expense |
|
24.72
-15.35%
|
29.21
-11.91%
|
33.16
+6.66%
|
31.08
|
| Other Gand A |
|
24.72
-15.35%
|
29.21
-11.91%
|
33.16
+6.66%
|
31.08
|
| Total Expenses |
|
93.33
-19.51%
|
115.95
-11.62%
|
131.19
+4.44%
|
125.62
|
| Operating Income |
|
-93.33
+19.51%
|
-115.95
+11.62%
|
-131.19
-4.44%
|
-125.62
|
| Total Operating Income As Reported |
|
-93.33
+19.51%
|
-115.95
+11.62%
|
-131.19
-4.44%
|
-125.62
|
| EBITDA |
|
-84.89
+21.01%
|
-107.48
+12.27%
|
-122.51
-2.81%
|
-119.15
|
| Normalized EBITDA |
|
-84.89
+21.01%
|
-107.48
+12.27%
|
-122.51
-2.81%
|
-119.15
|
| Reconciled Depreciation |
|
8.44
-0.38%
|
8.47
-2.52%
|
8.69
+34.33%
|
6.47
|
| EBIT |
|
-93.33
+19.51%
|
-115.95
+11.62%
|
-131.19
-4.44%
|
-125.62
|
| Net Income |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Pretax Income |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Net Non Operating Interest Income Expense |
|
2.68
-43.38%
|
4.74
-32.87%
|
7.06
+261.11%
|
1.95
|
| Net Interest Income |
|
2.68
-43.38%
|
4.74
-32.87%
|
7.06
+261.11%
|
1.95
|
| Interest Income Non Operating |
|
2.68
-43.38%
|
4.74
-32.87%
|
7.06
+261.11%
|
1.95
|
| Interest Income |
|
2.68
-43.38%
|
4.74
-32.87%
|
7.06
+261.11%
|
1.95
|
| Other Income Expense |
|
0.05
-36.59%
|
0.08
+54.72%
|
0.05
+2550.00%
|
0.00
|
| Other Non Operating Income Expenses |
|
0.05
-36.59%
|
0.08
+54.72%
|
0.05
+2550.00%
|
0.00
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Net Income From Continuing Operation Net Minority Interest |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Net Income From Continuing And Discontinued Operation |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Net Income Continuous Operations |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Normalized Income |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Net Income Common Stockholders |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Diluted EPS |
|
—
|
-1.31
+22.02%
|
-1.68
+39.13%
|
-2.76
|
| Basic EPS |
|
—
|
-1.31
+22.02%
|
-1.68
+39.13%
|
-2.76
|
| Basic Average Shares |
|
—
|
84.82
+14.96%
|
73.79
+64.61%
|
44.82
|
| Diluted Average Shares |
|
—
|
84.82
+14.96%
|
73.79
+64.61%
|
44.82
|
| Diluted NI Availto Com Stockholders |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
170.51
|
| Current Assets |
|
111.58
|
| Cash Cash Equivalents And Short Term Investments |
|
104.64
|
| Cash And Cash Equivalents |
|
45.68
|
| Other Short Term Investments |
|
58.96
|
| Receivables |
|
0.00
|
| Taxes Receivable |
|
0.00
|
| Prepaid Assets |
|
5.78
|
| Other Current Assets |
|
1.16
|
| Total Non Current Assets |
|
58.93
|
| Net PPE |
|
53.26
|
| Gross PPE |
|
77.60
|
| Accumulated Depreciation |
|
-24.34
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
20.31
|
| Construction In Progress |
|
1.73
|
| Other Properties |
|
29.95
|
| Leases |
|
25.61
|
| Investments And Advances |
|
0.00
|
| Other Non Current Assets |
|
5.68
|
| Total Liabilities Net Minority Interest |
|
31.09
|
| Current Liabilities |
|
22.73
|
| Payables And Accrued Expenses |
|
9.24
|
| Payables |
|
5.91
|
| Accounts Payable |
|
5.63
|
| Current Accrued Expenses |
|
3.33
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
8.70
|
| Total Tax Payable |
|
0.28
|
| Current Debt And Capital Lease Obligation |
|
4.32
|
| Current Capital Lease Obligation |
|
4.32
|
| Current Deferred Liabilities |
|
—
|
| Other Current Liabilities |
|
0.48
|
| Total Non Current Liabilities Net Minority Interest |
|
8.36
|
| Long Term Debt And Capital Lease Obligation |
|
8.11
|
| Long Term Capital Lease Obligation |
|
8.11
|
| Non Current Deferred Liabilities |
|
—
|
| Other Non Current Liabilities |
|
0.25
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
139.42
|
| Common Stock Equity |
|
139.42
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
68.33
|
| Ordinary Shares Number |
|
68.33
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
542.80
|
| Retained Earnings |
|
-403.28
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.11
|
| Other Equity Adjustments |
|
-0.11
|
| Total Equity Gross Minority Interest |
|
139.42
|
| Total Capitalization |
|
139.42
|
| Working Capital |
|
88.85
|
| Invested Capital |
|
139.42
|
| Total Debt |
|
12.42
|
| Capital Lease Obligations |
|
12.42
|
| Net Tangible Assets |
|
139.42
|
| Tangible Book Value |
|
139.42
|
| Available For Sale Securities |
|
—
|
| Investmentin Financial Assets |
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-68.26
+24.57%
|
-90.50
+11.34%
|
-102.07
+2.25%
|
-104.42
|
| Cash Flow From Continuing Operating Activities |
|
-68.26
+24.57%
|
-90.50
+11.34%
|
-102.07
+2.25%
|
-104.42
|
| Net Income From Continuing Operations |
|
-90.60
+18.48%
|
-111.13
+10.44%
|
-124.08
-0.34%
|
-123.67
|
| Depreciation Amortization Depletion |
|
8.44
-0.38%
|
8.47
-2.52%
|
8.69
+34.33%
|
6.47
|
| Depreciation |
|
—
|
8.47
-2.52%
|
8.69
+34.33%
|
6.47
|
| Depreciation And Amortization |
|
8.44
-0.38%
|
8.47
-2.52%
|
8.69
+34.33%
|
6.47
|
| Other Non Cash Items |
|
2.90
-23.26%
|
3.77
+12.69%
|
3.35
+35.97%
|
2.46
|
| Stock Based Compensation |
|
13.05
-20.94%
|
16.50
+7.79%
|
15.31
+33.50%
|
11.47
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
-2.46
+69.03%
|
-7.93
-40.42%
|
-5.65
-565.25%
|
-0.85
|
| Change In Prepaid Assets |
|
0.55
-36.17%
|
0.86
+748.51%
|
0.10
+103.44%
|
-2.93
|
| Change In Payables And Accrued Expense |
|
-0.90
+83.14%
|
-5.33
-419.10%
|
-1.03
-117.08%
|
6.01
|
| Change In Accrued Expense |
|
0.53
+111.21%
|
-4.75
-310.33%
|
2.26
-48.11%
|
4.35
|
| Change In Payable |
|
-1.43
-146.13%
|
-0.58
+82.30%
|
-3.28
-297.71%
|
1.66
|
| Change In Account Payable |
|
-1.43
-146.13%
|
-0.58
+82.30%
|
-3.28
-297.71%
|
1.66
|
| Change In Other Current Assets |
|
0.57
-12.96%
|
0.66
+209.15%
|
-0.60
+26.26%
|
-0.81
|
| Change In Other Current Liabilities |
|
-2.68
+35.02%
|
-4.12
+0.10%
|
-4.12
-32.63%
|
-3.11
|
| Investing Cash Flow |
|
56.08
+4858.71%
|
1.13
-97.68%
|
48.72
-41.76%
|
83.65
|
| Cash Flow From Continuing Investing Activities |
|
56.08
+4858.71%
|
1.13
-97.68%
|
48.72
-41.76%
|
83.65
|
| Net PPE Purchase And Sale |
|
-0.62
+39.71%
|
-1.02
+17.27%
|
-1.24
+93.99%
|
-20.63
|
| Purchase Of PPE |
|
-0.62
+39.71%
|
-1.02
+17.27%
|
-1.24
+93.99%
|
-20.63
|
| Capital Expenditure |
|
-0.62
+39.71%
|
-1.02
+17.27%
|
-1.24
+93.99%
|
-20.63
|
| Net Investment Purchase And Sale |
|
56.70
+2550.82%
|
2.14
-95.72%
|
49.98
-52.07%
|
104.27
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-87.07
-53.71%
|
-56.64
+59.68%
|
-140.48
|
| Sale Of Investment |
|
56.70
-36.44%
|
89.21
-16.33%
|
106.62
-56.44%
|
244.75
|
| Net Other Investing Changes |
|
—
|
0.02
+168.00%
|
-0.03
-412.50%
|
0.01
|
| Financing Cash Flow |
|
108.41
+127.03%
|
47.75
+1079.28%
|
4.05
-94.79%
|
77.77
|
| Cash Flow From Continuing Financing Activities |
|
108.41
+127.03%
|
47.75
+1079.28%
|
4.05
-94.79%
|
77.77
|
| Net Common Stock Issuance |
|
105.98
+126.63%
|
46.76
+1108.95%
|
3.87
-95.00%
|
77.39
|
| Common Stock Payments |
|
—
|
—
|
—
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
2.43
+146.00%
|
0.99
+44.72%
|
0.68
+79.47%
|
0.38
|
| Net Other Financing Charges |
|
—
|
—
|
-0.50
|
—
|
| Changes In Cash |
|
96.22
+331.19%
|
-41.62
+15.59%
|
-49.31
-186.51%
|
56.99
|
| Beginning Cash Position |
|
4.74
-89.77%
|
46.36
-51.54%
|
95.67
+147.37%
|
38.68
|
| End Cash Position |
|
100.97
+2029.19%
|
4.74
-89.77%
|
46.36
-51.54%
|
95.67
|
| Free Cash Flow |
|
-68.88
+24.74%
|
-91.53
+11.41%
|
-103.31
+17.39%
|
-125.05
|
| Amortization Of Securities |
|
0.41
+323.37%
|
-0.18
-158.41%
|
0.32
+202.61%
|
-0.31
|
| Common Stock Issuance |
|
105.98
+126.63%
|
46.76
+1108.95%
|
3.87
-95.00%
|
77.39
|
| Issuance Of Capital Stock |
|
105.98
+126.63%
|
46.76
+1108.95%
|
3.87
-95.00%
|
77.39
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-06 View
- 8-K2026-05-06 View
- 10-K2026-03-11 View
- 8-K2026-03-11 View
- 8-K2026-03-05 View
- 42026-02-26 View
- 42026-02-24 View
- 42026-02-17 View
- 42026-02-17 View
- 42026-02-17 View
- 42026-02-12 View
- 42026-02-05 View
- 42026-02-05 View
- 42026-02-05 View
- 8-K2026-01-30 View
- 8-K2026-01-02 View
- 8-K2025-12-12 View
- 8-K2025-12-11 View
- 42025-11-17 View
- 42025-11-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|